Key result
High KCNJ5 gene expression is linked to worse survival in an Indian pancreatic cancer cohort.
Why the study?
Conventional therapies for pancreatic cancer are mostly futile, and the fundamental mechanisms by which ion channels contribute to cancer hallmarks remain uncertain.
Observational (n=20)
KCNJ5 is identified as a significantly upregulated onco-channel gene associated with adverse survival in Indian pancreatic cancer patients, presenting a potential therapeutic target.
May inform pancreatic cancer prognosis; hypothesis-generating for therapeutic targeting pending validation.
BACKGROUND: Pancreatic cancer (PanCa) is one of the most lethal cancers (survival ~ 12%). As the conventional therapeutic interventions are mostly futile, a deep understanding of the disease pathophysiology is an urgent need. Ion channels, located on cell membrane, contribute significantly to cancer hallmarks, through dysregulation of various ion translocation; however, the fundamental mechanisms remain uncertain. METHODS: To identify these oncochannels in Indian cohort of PanCa, we utilized 450 K data, published in our previous study, and identified potential pathways involved. Their expressions were evaluated using TCGA data and an independent Indian paired patient cohort (n = 20). The top genes were further validated using GEO and ScRNA seq dataset. Potential target ability of KCNJ5 was identified through molecular dynamic based drug designing. RESULTS: A set of 7 differentially methylated and differentially expressed genes of ion-channel proteins namely KCNJ5, CACNB2, KCNA3, KCNA6, RASA3, GABBR2 and CLIC5 were identified in Indian PanCa cohort only. KCNJ5 was significantly upregulated and associated with worse survival in Indian cohort, whereas downregulated in TCGA and other Caucasians patient populations. Two TFs controlling the KCNJ5 expression are POU2F1 and POU3F1. Few predicted small molecules targeting Kcnj5 are, Amiloride, Vernakalant hydrochloride, Dalfampridine, Glyburide and Levcromakalim. It also showed notable interactions with a steroidal anticancer agent, protodioscin. CONCLUSION: An onco-channel gene, KCNJ5 significantly upregulated, and showing adverse survival in highly expressed KCNJ5 group in Indian cohort of PanCa, can be targeted with Amiloride, Vernakalant hydrochloride, Dalfampridine, Glyburide Levcromakalim and protodioscin. This understanding can lead to novel target identification for PanCa therapy development.
No takes yet. Share an insight, caveat, or question.
Bararia et al. (2025) conducted an observational in Pancreatic cancer (n=20). KCNJ5 gene expression vs. Low KCNJ5 expression was evaluated on Survival. High KCNJ5 gene expression was significantly upregulated and associated with worse survival in an Indian pancreatic cancer cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: